110 related articles for article (PubMed ID: 14967462)
1. Epidermal growth factor receptor inhibitors in clinical development.
Dancey J
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):1003-7. PubMed ID: 14967462
[TBL] [Abstract][Full Text] [Related]
2. Targeting epidermal growth factor receptor--are we missing the mark?
Dancey JE; Freidlin B
Lancet; 2003 Jul; 362(9377):62-4. PubMed ID: 12853203
[TBL] [Abstract][Full Text] [Related]
3. EGFR inhibition in NSCLC: the emerging role of cetuximab.
Herbst RS
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S41-51. PubMed ID: 19780245
[TBL] [Abstract][Full Text] [Related]
4. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
5. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.
Langer CJ
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):991-1002. PubMed ID: 14967461
[TBL] [Abstract][Full Text] [Related]
6. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
Ciardiello F; Tortora G
Clin Cancer Res; 2001 Oct; 7(10):2958-70. PubMed ID: 11595683
[TBL] [Abstract][Full Text] [Related]
7. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.
Raben D; Helfrich B; Bunn PA
Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):27-38. PubMed ID: 15142632
[TBL] [Abstract][Full Text] [Related]
9. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
Tortora G; Caputo R; Damiano V; Melisi D; Bianco R; Fontanini G; Veneziani BM; De Placido S; Bianco AR; Ciardiello F
Clin Cancer Res; 2003 Apr; 9(4):1566-72. PubMed ID: 12684433
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?
Normanno N; Maiello MR; De Luca A
J Cell Physiol; 2003 Jan; 194(1):13-9. PubMed ID: 12447985
[TBL] [Abstract][Full Text] [Related]
11. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
Baselga J; Arteaga CL
J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
[TBL] [Abstract][Full Text] [Related]
12. The EGF receptor family as targets for cancer therapy.
Mendelsohn J; Baselga J
Oncogene; 2000 Dec; 19(56):6550-65. PubMed ID: 11426640
[TBL] [Abstract][Full Text] [Related]
13. The HER receptor family: a rich target for therapeutic development.
Mass RD
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):932-40. PubMed ID: 14967453
[TBL] [Abstract][Full Text] [Related]
14. Targeting epidermal growth factor receptor signaling: early results and future trends in oncology.
Lage A; Crombet T; González G
Ann Med; 2003; 35(5):327-36. PubMed ID: 12952019
[TBL] [Abstract][Full Text] [Related]
15. Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer.
Kim DW; Choy H
Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):11-20. PubMed ID: 15142630
[TBL] [Abstract][Full Text] [Related]
16. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
Janmaat ML; Kruyt FA; Rodriguez JA; Giaccone G
Clin Cancer Res; 2003 Jun; 9(6):2316-26. PubMed ID: 12796401
[TBL] [Abstract][Full Text] [Related]
17. Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors.
Ochs JS
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):941-9. PubMed ID: 14967454
[TBL] [Abstract][Full Text] [Related]
18. Radiation combined with EGFR signal inhibitors: head and neck cancer focus.
Harari PM; Huang S
Semin Radiat Oncol; 2006 Jan; 16(1):38-44. PubMed ID: 16378905
[TBL] [Abstract][Full Text] [Related]
19. Combination epidermal growth factor receptor inhibition and radical radiotherapy for NSCLC.
Rogers SJ; Harrington KJ; Eccles SA; Nutting CM
Expert Rev Anticancer Ther; 2004 Aug; 4(4):569-83. PubMed ID: 15270661
[TBL] [Abstract][Full Text] [Related]
20. Interference with EGFR signaling: paradigm for improving radiation response in cancer treatment.
Raben D; Bianco C; Helfrich B; Weng E; Ciardiello F; Harari P
Expert Rev Anticancer Ther; 2002 Aug; 2(4):461-71. PubMed ID: 12647989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
